Table of Content

08 February 2015, Volume 42 Issue 2 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Clinical research on systemic chemotherapy concurrent whole brain radiotherapy for brain metastases from nonsmall cell lung cancer Wang Xiang, Zhang Shiqiang, Zhang Youwei 2015, 42 (2):  81-83.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.001 Abstract ( 321 )   PDF (757KB) ( 1419 )   Save ObjectiveTo explore the feasibility and safety of systemic chemotherapy concurrent whole brain radiotherapy (WBRT) for nonsmall cell lung cancer (NSCLC) with brain metastases. MethodsEighty cases of NSCLC patients with brain metastases were divided into observation group (40 cases) and the control group (40 cases) according to random number table. Patients were given systemic chemotherapy synchronous WBRT or sequential WBRT. ResultsThe ⅠⅣ degree leukocytopenia incidences of the two groups were 12.5%, 25.0%, 25.0%, 0.0 and 30.0%, 25.0%, 12.5%, 15.0%, and there was statistical significance (χ2=12.12, P<0.05). In the observation group, the total remission rate was 20% (8/40), and it was 22.5% (9/40) in the control group, with no significant difference (χ2=1.79, P>0.05). The median progression free survival of the observation group and of the control group were (3.5±2.3) months and (3.6±1.1) months, respectively, with no significant difference (t=5.23, P>0.05). But the 1years survival rate in the observation group was 37.5% (15/40), significantly higher than that in the control group (17.5%, 7/40), which had statistical significance (χ2=9.11, P<0.05). ConclusionThe safety of systemic chemotherapy synchronous WBRT for NSCLC patients with brain metastases is higher, with good curative effect and strong application feasibility. References | Related Articles | Metrics

Radiotherapy curative effects for single or multiple brain metastases Qin Xiaoling, Yang Fan, Yu Zhilong 2015, 42 (2):  84-87.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.002 Abstract ( 482 )   PDF (687KB) ( 1329 )   Save ObjectiveTo investigate the better radiation modalities for single and multiple brain metastases. MethodsBetween July 2005 and July 2008, 50 patients with single or multiple brain metastases were retrospectively analyzed. The primary cancer of all patients were controlled. Thirty patients with whole brain radiotherapy and stereotactic radiosurgery were included in the combination group, and 20 patients with stereotactic radiosurgery were included in another group. Stereotactic radiosurgery prescription doses of 45%75% isodose line were used to wrap around the planning target, which was 1520 Gy in edge and 3045 Gy in center. Stereotactic radiosurgery was performed once. Whole brain radiotherapy total dose was 40 Gy, which was given to patients by 2 Gy in 1 fraction, 1 fraction every day, 5 times every week.  ResultsThe efficient rate of combination group was 90% (27/30), and single group was 60% (12/20). It was obviously higher in combination group (χ2=6.294, P=0.012). For combination group, the 1year survival rate was 50% (15/30) and the 2year survival rate was 30% (9/30). However, for another group, the 1year survival rate was 35% (7/20) and the 2year survival rate was 15% (3/20). The survival rates of two groups were no difference (χ2=1.096, P=0.295; χ2=1.480, P=0.224). There were no patients survived more than 3 years in both groups. Stratified analyses showed that the 1year survival rates of the patients with single brain metastasis were no difference in two groups (100.0% vs 66.7%， χ2=1.556, P=0.212). Whereas the 1year survival rate in combination group of the patients with multiple brain metastases was higher than that in single group (42.3% vs 29.4%， χ2=11.023, P=0.001). There were no statistically significant differences in 2year survival rates in both groups with single and multiple brain metastases (75.0% vs 66.7%， χ2=1.200，P=0.273; 23.1% vs 5.9%， χ2=3.782，P=0.052). ConclusionWhole brain radiotherapy and stereotactic radiosurgery are important treatment modalities for single or multiple brain metastases. The optimal treatment modality for single brain metastasis is stereotactic radiosurgery, while it is a good choice to make whole brain radiotherapy and stereotactic radiosurgery for multiple brain metastases. References | Related Articles | Metrics

Effect of adoptive immunotherapy with CIK cells combined with interleukin-2 on immunologic function and life qualities of patients with nonsmall cell lung cancer Xue Ming, Guo Mingkun 2015, 42 (2):  88-90.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.003 Abstract ( 464 )   PDF (679KB) ( 1469 )   Save Objective To investigate the changes of immunologic functions and life qualities after the autocytokine induced killer (CIK) cells combined with interleukin2(IL2) being transfused back to the patients with nonsmall cell lung cancer (NSCLC). MethodsThirtyeight NSCLC patients were enrolled, and 19 patients received not only chemotherapy and radiotherapy but also adoptive immunotherapy with CIK cells combined with IL2 compared with the other 19 patients who only accepted radiotherapy and chemotherapy. The changes of immunologic functions and life qualities after the CIK cells combined with IL2 being transfused back to the patients with NSCLC were observed. Immune targets of the treatment group and control group, such as peripheral blood CD3+, CD4+, CD8+ T cell percentage, ratio of CD4+/CD8+ and Th1/Th2, were observed at the end and after 3 month of the radiation and chemotherapy. ResultsBoth of the two groups were neither having obvious adverse reactions. After CIK cells combined with IL2 treatment, the life qualities of patients improved, such as 18 cases of  mental improvement, 15 cases of appetite improvement, 12 cases of sleep improvement, and 3 cases of fatigue symptoms improvement. The percentage of CD3+, CD4+ cells in the treatment group increased ［（66.39±9.22）% vs （42.98±7.23）%， t=5.45，P=0.00；（32.27±3.75）% vs （26.38±2.51）%， t=5.73，P=0.00］, the percentage of CD8+ cells declined ［（17.51±1.85）% vs （20.90±2.31）%， t=5.21，P=0.00］, the rate of CD4+/CD8+ increased and the rate of Th1/Th2 obversed ［（1.86±0.32） vs （1.27±0.19）， t=7.13，P=0.00；（1.15±0.48） vs （0.91±0.30）， t=2.42，P=0.02］. There were significant differences between the two groups. ConclusionAdoptive immunotherapy with CIK cells combined with IL2 is safe in clinical, which can improve the immunologic functions and life qualities of the patients with NSCLC. References | Related Articles | Metrics

Analysis of the failure pattern in 110 patients with radical resection of gastric cancer Zeng Hai, Zhang Weijia, Li Shuang 2015, 42 (2):  91-94.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.004 Abstract ( 469 )   PDF (748KB) ( 1489 )   Save ObjectiveTo find the reasonable treatment strategy by analyzing the failure pattern and survival rates of radical resection of gastric cancer. MethodsData were collected from 110 patients with radical resection and adjuvant treatment of gastric cancer, counted up the number of cases that failure in different ways. The survival rate after operation was calculated by KaplanMeier. The chisquare test was used to find the differences in survival rates between different differentiation, location and gender. Results1, 3, 5year survival rates of 110 cases were 83.64% (92/110), 46.36% (51/110), 35.45% (39/110), respectively. Malignant ascites was the main failure type for postoperative of gastric cancer, approximately accounting for 41.51% (22/53), abdominal lymph node metastasis accounting for 30.19% (16/53), anastomotic recurrence accounting for 13.21% (7/53), abdominal implantation and mesenteric metastasis accounting for 9.43% (5/53), organ metastasis accounting for 5.66% (3/53). The 5year local failure rate of concurrent chemoradiotherapy group was a little lower than that in adjuvant chemotherapy alone group (15.00%∶22.22%). The 1year survival rates of adjuvant chemotherapy alone and concurrent chemoradiotherapy group were 84.44% and 80.00% respectively, with no significant difference (χ2=0.236, P=0.627). However, the 3, 5year survival rates of the two groups were 66.67% vs 40.00% and 53.33% vs 20.00% respectively, with statistically significant differences (χ2=4.930, P=0.026; χ2=7.294, P=0.007). Conclusion Peritoneal metastasis is the most common failure pattern for the patients with gastric cancer who received radical operation and adjuvant treatment. The relapse rate of concurrent chemoradiotherapy group is lower than that in adjuvant chemotherapy alone group, but the overall survival rate is similar. References | Related Articles | Metrics

Expressions of IGF-1R and IGFBP-3 in colon cancer metastasis and their correlations with lymphatic metastasis Li Tingting, Kang Junpeng, Guo Shuqin 2015, 42 (2):  95-98.  doi: 10.3760/cma.j.issn.1673422X.2015.02.005 Abstract ( 410 )   PDF (988KB) ( 1470 )   Save ObjectiveTo investigate the expressions of insulinlike growth factor receptor1 (IGF1R) and insulinlike growth factor binding protein3 (IGFBP3) and their correlations with clinicopathological parameters in the primary colon cancer, as well as their roles in lymph node metastasis of colon cancer. MethodsThe expressions of IGF1R and IGFBP3 in 78 cases of colon cancer tissues and 78 cases of normal colon mucosa tissues were detected by SP immunohistochemical technology and the correlations between the expressions and the clinical pathological parameters of colon cancer were analyzed. ResultsThe positive rate of IGF1R in colon cancer (66.7%, 52/78) was significantly higher than that in control group (24.4%, 19/78), χ2=28.150, P=0.000. The positive rate of IGFBP3 in colon cancer (73.1%, 57/78) was significantly lower than that in control group (89.7%, 70/78), χ2=7.158, P=0.007. IGF1R expression in colon cancer was significantly correlated with the invasion (χ2= 5.804, P=0.016), TNM stage (χ2=5.246, P=0.022) and lymph node metastasis (χ2=12.955, P=0.000). IGFBP3 expression in colon cancer was significantly correlated with the TNM stage (χ2=7.096, P=0.008), lymph node metastasis (χ2=5.893, P=0.015) and distant metastasis (P=0.003). Both with other factors had no significant correlation (P>0.05). IGF1R expression and IGFBP3 expression showed a negative correlation (r=-0.245, P=0.03). ConclusionThe over expression of IGF1R and low expression of IGFBP3 are associated with TNM stage and lymph node metastasis in colon cancer. IGF1R and IGFBP3 may become new targets of the treatment of colon cancer. References | Related Articles | Metrics

Relationship between UGT1A1*28 gene polymorphism and delayed diarrhea caused by FOLFIRI treatment Li Deng, Wang Yan, Wang Lu, Zhu Yiping 2015, 42 (2):  99-102.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.006 Abstract ( 435 )   PDF (688KB) ( 1416 )   Save ObjectiveTo analyze the relationship between UDPglucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and delayed diarrhea caused by FOLFIRI treatment. MethodsTwo hundred and one blood samples were taken from patients with metastatic digestive tract tumor before chemotherapy by FOLFIRI and then the UGT1A1*28 genetic polymorphism was performed. All the cases treated with FOLFIRI were chosen to be observed and recorded by situation of the delayed diarrhea during chemotherapy, and to analyze the relationship between UGT1A1*28 genetic polymorphism and grade 3 and 4 delayed diarrhea. ResultsThe distributions of the genotypes in 201 metastatic digestive tract tumor patients were as follows: UGT1A1*28 wildtype genotype TA6/6 (155, 77.11%), heterozygous genotype TA6/7 together with homozygous genotype TA7/7 (46, 22.89%). In the 201 cases, the incidences of grade 1 and 2 delayed diarrhea in the patients carrying wildtype genotype and mutant type were respectively 45.16% (70/155), 39.13% (18/46). The incidences of grade 3 and 4 delayed diarrhea were respectively 9.68% (15/155), 19.57% (9/46), with no statistical difference (χ2=3.318, P=0.190). ConclusionThe UGT1A1*28 polymorphism TA6/7 or TA7/7 can not increase the risk of grade 3 or more severe delayed diarrhea for the patients with metastatic digestive tract tumor after receiving FOLFIRI treatment. References | Related Articles | Metrics

Meta analysis of brain metastases ideal treatment mode Li Ying, Fang Xiaomeng, Jiang Da, Dong Qian, Zhang Zengye, Zheng Fei 2015, 42 (2):  103-108.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.007 Abstract ( 493 )   PDF (2927KB) ( 1190 )   Save ObjectiveTo explore the ideal treatment mode of brain metastases by Metaanalysis. MethodsArticles were searched for from the databases at home and abroad using English and Chinese keywords. Searching time limited from the databases setting up to December 30, 2012. Jadad score was applied to evaluate the qualities of literatures. RevMan5.0 software was applied to perform the Metaanalysis. A totle of 25 articles including 2 750 patients were eligible for the Metaanalysis, which divided into groups with different treatment. ResultsCompared with monotherapy, combined therapy improved 1year survival  (OR=0.58, 95%CI： 0.46~0.71， P＜0.000 01). In combined therapy groups, compared with two methods, three kinds of therapies improved 1year survival (OR=0.63, 95%CI： 0.50~0.80， P=0.000 1). Compared with local therapy only or systemic therapy only, systemic combined local therapy improved 1year survival (OR=0.68, 95%CI： 0.53~0.86， P=0.001; OR=0.59, 95%CI： 0.41~0.86， P=0.006). In systemic combined local therapy groups, three kinds of treatments improved 1year survival compared with two methods (OR=0.52, 95%CI： 0.35~0.78， P=0.002). Compared with nonmolecular targeted therapy, molecular targeted therapy improved 1year survival (OR=0.76, 95%CI： 0.67~0.87， P＜0.000 1). ConclusionThe reasonable treatment for patients with brain metastases is combined treatment with operation, radiotherapy and chemotherapy. There is better curative effect added molecular targeted therapy based on original scheme, if patients have targeted therapy indications. References | Related Articles | Metrics

Meta analysis of lymph node metastasis pattern of nasopharyngeal carcinoma Xu Chao, Bao Yun, Zhou Juying, Tu Yu 2015, 42 (2):  109-114.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.008 Abstract ( 609 )   PDF (2420KB) ( 1315 )   Save ObjectiveBased on the published articles, this paper aims to study the pattern and probability of lymph nodes metastasis in nasopharyngeal carcinoma (NPC) and establish a radiotherapy standard for selecting and delineation of clinical target volume of neck lymphatics for NPC patients with N0 or N1.MethodsClinical trials about NPC by MRI as the main or only diagnostic imaging way were collected and extracted from database, such as WanFang, CBM, PubMed, Cochrane Library. Statistical analyses were performed using Stata software, version 12.0. ResultsTwentyone clinical trials from 963 original articles were included in this analysis. The most commonly involved regions included retropharyngeal (67%) and level Ⅱ lymph nodes (71%). The overall probability of levels Ⅲ, Ⅳ and Ⅴnodal involvement were 37%, 14% and 21%, respectively. Lowrisk node groups included levels ⅠA, ⅠB, Ⅵ nodes, and the rates of lymph node metastasis were 0, 2%, 2% and 1%, respectively. Nodal metastases followed an orderly pattern of topdown, and the probability of "skip" metastasis between levels varied between 0.5%～7.9%. ConclusionLymph node metastasis in NPC follows a predictable and orderly pattern. The rarity of metastasis in certain nodal groups and "skip" metastasis suggest that reduced treatment volume is feasible in conformal radiotherapy for NPC patients with N0 or N1. References | Related Articles | Metrics

DDX43 gene and tumors Chen Qin, Lin Jiang, Qian Jun 2015, 42 (2):  115-117.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.009 Abstract ( 405 )   PDF (679KB) ( 1518 )   Save DEAD (AspGluAlaAsp) box polypeptide 43 (DDX43) plays an important role in the malignant proliferation, drug resistance of tumor cells as well as neoplasm immunotherapy. The overexpression of DDX43 has been found in various solid tumors and some hematologic malignancies. The hypomethylation of DDX43 gene promoter is identified in chronic myeloid leukemia, acute myeloid leukemia and myelodysplastic syndrome, which is correlated with DDX43 overexpression and the prognosis of these diseases. References | Related Articles | Metrics

Research progress of MEG3 long noncoding RNA Chen Ruidong, Tang Wen, Hu Duanmin 2015, 42 (2):  118-121.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.010 Abstract ( 390 )   PDF (685KB) ( 1516 )   Save Maternally expressed gene 3 (MEG3) is a tumorsuppressing gene, and MEG3 RNAs, its products, are a series of long noncoding RNAs. The MEG3 gene is lost in kinds of human tumors, further more, the methylation of related DNA region is directly associated with the deficiency of MEG3 expression. Studies show that MEG3 gene and MEG3 RNAs can inhibit cell proliferation and induce apoptosis, which is associated with the fuction of tumor suppressor gene p53. References | Related Articles | Metrics

Glutamine and tumor metabolism and their applications in nuclear medicine Liu Fei, Zhu Hua, Lin Xinfeng, Luo Zheng, Li Nan, Yang Zhi 2015, 42 (2):  122-125.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.011 Abstract ( 458 )   PDF (685KB) ( 1704 )   Save Many tumors depend on glutamine for energy. Glutamine metabolism is recognized as a distinctive feature in addition to Warburg effect in tumors. Nuclear medicine molecular tracer techniques represented by positron emission tomography (PET) provide a good means for early diagnosis and prognosis of tumors. PET imaging can detect glutamine metabolism region in tumors noninvasively, which can provide new diagnosis and therapeutics for glutamineaddicted tumors. References | Related Articles | Metrics

Microenvironment and the occurrence and development of cancer stem cells hang Xiaoying, Wang Xiaofang 2015, 42 (2):  126-129.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.012 Abstract ( 445 )   PDF (685KB) ( 1576 )   Save The occurrence and development of tumor depends not only on the tumor itself, but also depends on the soil survival of tumor cells, that is the tumor microenvironment. Studies confirm that the changes of blood vessels and hypoxic of tumor microenvironment maintain the stemness of cancer stem cell, and further strengthen the ability of tumor invasion and metastasis. Studying the molecular mechanism of tumor development from angiogenesis and lack of oxygen can provide new ideas for the clinical targeted therapy. References | Related Articles | Metrics

CIK cells and their application in the tumor treatment Shu Xin, Wang Zhiyu 2015, 42 (2):  130-133.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.013 Abstract ( 387 )   PDF (686KB) ( 1513 )   Save Cytokineinduced killer (CIK) cells play important roles in the treatment of solid tumors. In particular, they have broad application prospects for the patients with recurrence or metastasis. Although recently CIK treatment strategy has achieved encouraging results in preclinical studies, there are still some difficulties in the clinical applications. Some key issues remain to be resolved, such as how to ensure that the antitumor immune effector can be a lot of amplified and can stay longer in the body, how to selectively kill tumor cells, and how to ensure the security of application. References | Related Articles | Metrics

Therapeutic progression of recurrent nasopharyngeal carcinoma Ma Xuan, Li Xiaojiang 2015, 42 (2):  134-137.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.014 Abstract ( 235 )   PDF (689KB) ( 1610 )   Save Although radiotherapy is still the preferred treatment of nasopharyngeal carcinoma and the curative effect is satisfactory at present, but it is hard to avoid the recurrence in a part of patients after active treatment. The therapies for patients with recurrence have certein difficulty. In recent years, the salvage treatments such as modern radiotherapy, chemotherapy and surgery for the patients with recurrence are used and the clinical effects are accepted. References | Related Articles | Metrics

Advances of BRCA1, BRCA2 mutation and their clinical applications Li Chen, Huang Yan 2015, 42 (2):  138-140.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.015 Abstract ( 526 )   PDF (674KB) ( 1571 )   Save The occurrence of breast cancer is closely related to genetic factors. BRCA1 and BRCA2, breast cancer susceptibility genes, play important roles in the occurrence and development of breast cancer. The researches on germline mutations in BRCA1 and BRCA2 are of great significance in prevention, diagnosis and treatment of breast cancer. References | Related Articles | Metrics

Metastatic mechanisms of breast cancer Zhong Jingmin, Zeng Liang 2015, 42 (2):  141-143.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.016 Abstract ( 349 )   PDF (676KB) ( 1583 )   Save Breast neoplasm shows high rate of incidence and mortality among females. Although there are a variety of treatments for breast neoplasm, breast neoplasm metastasis is still an intractable medical problem. At present, the related mechanisms of breast neoplasm metastasis are as follows: epithelialmesenchymal transition, dissolution of extracellular matrix, circulating tumor cells or disseminated tumor cells, tumor vessels and tumor microenvironment. Making clear of the related mechanisms of breast neoplasm metastasis has certain guiding significance for the prediction and treatmence of breast neoplasm metastasis. References | Related Articles | Metrics

microRNAs and lung cancer Xiang Min, Zhu Ling, Chen Yan, Liu Xin, Wang Xicai 2015, 42 (2):  144-146.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.017 Abstract ( 348 )   PDF (679KB) ( 1505 )   Save microRNAs (miRNAs) are short nonproteincoding RNAs, which play important roles in the cell proliferation, differentiation, apoptosis, as well as activation of oncogenic and antioncogenic signals. Researches show that the abnormal expressions of miRNAs are closely related to the tumorigenesis, histological type, diagnosis, treatment and prognosis of lung cancer. So miRNAs may be the most potential and promising therapeutic targets for lung cancer. References | Related Articles | Metrics

Clinicopathological characteristics, diagnosis and treatment of combined small cell lung cancer Men Yu, Hui Zhouguang 2015, 42 (2):  147-149.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.018 Abstract ( 1576 )   PDF (681KB) ( 1835 )   Save Combined small cell lung cancer (CSCLC) is a special subtype of small cell lung cancer (SCLC), which has a low incidence and diagnostic rate. However,  the incidence and diagnostic rate appear an increasing tendency recently. The clinical features of CSCLC are similar to the pure SCLC, while it has a relatively limited stage. The main treatment pattern of CSCLC is multimodality therapy, though the response to chemotherapy in CSCLC is relatively poor. Survival between patients with CSCLC versus SCLC is similar. KPS, stage, composite components, tumor location and diameter, surgery margin are prognostic factors. Radiotherapy can benefit for the patients with ⅢA/ⅢB disease, positive lymph nodes, or with more metastatic lymph nodes after surgery. References | Related Articles | Metrics

Correlation between obesity and ovarian cancer Li Xiahui, Zhang Xuemei, Jiang Kui 2015, 42 (2):  150-152.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.019 Abstract ( 504 )   PDF (678KB) ( 1588 )   Save Obesity increases the risk of ovarian cancer, and it is associated with the poor prognosis of ovarian cancer. Its pathogenic mechanism may be associated with the increased level of serum estrogen, insulin and insulinlike growth factors1 induced by obesity and a variety of adipocytokines, which has an impact on the therapeutic result and prognosis of ovarian cancer. Maintaining a proper weight may prevent the development of ovarian cancer. References | Related Articles | Metrics

Reirradiation of recurrent cervical cancer Zhang Xiang, Yu Hua 2015, 42 (2):  153-156.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.020 Abstract ( 540 )   PDF (686KB) ( 1387 )   Save Pelvic exenteration, first line salvage therapy for selected recurrent cervical cancer patients, is accompanied by a high operative mortality and loss of structure and function of pelvic organs. Advances in radiation therapy, especially 3dimensional brachytherapy and stereotactic body radiotherapy, provide the opportunity to achieve similar efficacy of pelvic exenteration with acceptable complications and protect the structure and function of pelvic organs. References | Related Articles | Metrics

Mechanism of NLRC5 in diffuse large B-cell lymphoma Quan Yanlong, Zhou Yingqiong 2015, 42 (2):  157-160.  doi: 10.3760/cma.j.issn.1673-422X.2015.02.021 Abstract ( 416 )   PDF (688KB) ( 1257 )   Save Diffuse large Bcell lymphoma (DLBCL) is the most common malignant lymphoma in China, which mostly starting from the lymph nodes. The studies find that the expression of NLRC5, member of nucleotidebinding oligomerization domainlike receptor (NLR) family, is evident in the lymphoid cells, which is likely to be an important basis for lymphocyte tumorigenesis. NLRC5 can block the nuclear factorκB (NFκB), a core component of signal transduction pathway,  and affect the development of tumor. While continuing activation of NFκB is a necessary condition for DLBCL cell survival. Therefore, NLRC5 is likely to inhibit excessive inflammation, thereby inhibiting the function of DLBCL, which promises to be a new target for immunotherapy treatment of DLBCL. References | Related Articles | Metrics